@article{ref1,
title="The vernacular of risk - rethinking direct-to-consumer advertising of pharmaceuticals",
journal="New England journal of medicine",
year="2015",
author="Greene, Jeremy A. and Watkins, Elizabeth S.",
volume="373",
number="12",
pages="1087-1089",
abstract="Aside from New Zealand, the United States is the only country with a strong pharmaceutical regulatory infrastructure that allows direct-to-consumer advertising (DTCA) of prescription drugs in print, broadcast, and electronic media. U.S. consumers are accustomed to full-page ads in newspapers and magazines detailing a drug's benefits - followed by another page of fine print in which its contraindications, risks, and side effects are spelled out in minute detail and equally minute print. That may soon change, however, as the Food and Drug Administration (FDA) moves to enact new regulations regarding risk communication in DTCA. Earlier this year, the FDA sought. . .<p /> <p>Language: en</p>",
language="en",
issn="0028-4793",
doi="10.1056/NEJMp1507924",
url="http://dx.doi.org/10.1056/NEJMp1507924"
}